Incorporation of antimicrobial compounds in mesoporous silica film monolith

Biomaterials

Volumn 30, Issue 29, 2009, Pages 5729-5736

  Izquierdo Barba, Isabel ^a,b,c   Vallet Regí, María ^a,b   Kupferschmidt, Natalia ^c,d   Terasaki, Osamu ^c   Schmidtchen, Artur ^e   Malmsten, Martin ^d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Antimicrobial; Chlorhexidine; LL 37; Mesoporous; Silica

Indexed keywords

ANTI-MICROBIAL AGENT; ANTIBACTERIAL DRUGS; ANTIMICROBIAL; ANTIMICROBIAL COMPOUNDS; ANTIMICROBIAL PEPTIDE; BACTERICIDAL ACTION; BACTERICIDAL PROPERTIES; CAPSULE FORMATION; CHLORHEXIDINE; FTIR; IMPLANTABLE MATERIALS; LL-37; LOW MOLECULAR WEIGHT; LOW TOXICITY; MESOPOROUS; MESOPOROUS SILICA; MESOPOROUS SILICA FILM; MTT ASSAYS; NEGATIVE CONTROL; ONE-POT SYNTHESIS; PORE WALL; RELEASE RATE; STAPHYLOCOCCUS AUREUS; SURFACE COATINGS; TEM; XRD;

AMINES; ASSAYS; ESCHERICHIA COLI; FOURIER TRANSFORM INFRARED SPECTROSCOPY; SILICA; TOXICITY;

MESOPOROUS MATERIALS;

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHLORHEXIDINE; LACTATE DEHYDROGENASE; SILICON DIOXIDE;

ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG RELEASE; ENCAPSULATION; ENZYME RELEASE; ESCHERICHIA COLI; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ADSORPTION; ANTI-BACTERIAL AGENTS; DRUG CARRIERS; DRUG COMPOUNDING; MATERIALS TESTING; MEMBRANES, ARTIFICIAL; POROSITY; SILICON DIOXIDE;

ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 68549110160     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.07.003     Document Type: Article

References (44)

1. Yanagisawa T., Shimizu T., Kuroda K., and Kato K. The preparation of alkyltrimethylammonium-kanemite complexes and their conversion to microporous materials. Bull Chem Jpn 63 (1990) 988-992
2. Kresge C.T., Leonowicz M.E., Roth W.J., Vartuli J.C., and Beck J.S. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359 (1992) 710-712
3. Vallet-Regi M., Ramila A., del Real R.P., and Perez-Pariente J. A new property of MCM-41: drug delivery system. Chem Mater 13 (2001) 308-311
4. Vallet-Regi M., Balas F., and Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed 47 (2007) 7548-7558
5. Balas F., Manzano M., Colilla M., and Valle-Regi M. l-Trp adsorption into silica mesoporous materials to promote bone formation. Acta Biomaterialia 4 (2008) 514-522
6. Son Y.H., Park M., Choy Y.B., Choi H.R., Kim D.S., Park K.C., et al. One-pot synthetic route to polymer-silica assembled capsule encased with nonionic drug molecule. Chem Commun 27 (2007) 2799-2801
7. Vallet-Regi M., Balas F., Colilla M., and Manzano M. Bone-generative bioceramic implants with drug and protein controlled delivery capability. Prog Solid State Chem 36 (2008) 163-191
8. Vallet-Regi M. Ordered mesoporous materials in the context of drug delivery systems and bone tissue engineering. Chem Eur J 12 (2006) 5934-5943
9. Qu F., Zhu G., Lin H., Sun J., Zhang D., Li S., et al. Drug self-templated synthesis of ibuprofen/mesoporous silica for sustained release. Eur J Inorg Chem 19 (2006) 3943-3947
10. Anglin E.J., Cheng L., Freeman W.R., and Sailor M.J. Porous silicon in drug delivery devices and materials. Adv Drug Deliv Rev 60 (2008) 1266-1277
11. Slowing Vivero-Escoto II J.L., Wu C.W., and Lin V.S.Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60 (2008) 1278-1288
12. Salonen J., Laitinen L., Kaukonen A.M., Tuura J., Björkqvist M., Heikkilä T., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Controlled Release 108 (2005) 362-374
13. Foraker A.B., Walczak R.J., Cohen M.H., Boiarski T.A., Grove C.F., and Swaan P.W. Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res 20 (2003) 110-116
14. Lai C.Y., Trewyn B.G., Jeftinija D.M., Jeftinija K., Xu S., Jeftinija S., et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc 125 (2003) 4451-4459
15. Gao C., Izquierdo-Barba I., Nakase I., Futaki S., Ruan J., Sakamoto K., et al. Mesostructured silica based delivery system for a drug with a peptide as a cell-penetrating vector. Micropor Mesopor Mater 122 (2009) 201-207
16. Dürr U.H.N., Sudheendra U.S., and Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758 (2006) 1408-1425
17. French G.L. Clinical impact and relevance of antibiotics resistance. Adv Drug Deliv Rev 57 (2005) 1514-1527
18. Schierholz J.M., and Beuth J. Implant infections: a haven for opportunistic bacteria. J Hosp Infect 49 (2001) 87-93
19. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
20. Toke O. Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers 80 (2005) 717-735
21. Nizet V. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr Issues Mol Biol 8 (2006) 11-26
22. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Microbiol 3 (2005) 238-250
23. Hancock R.E., and Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24 (2006) 1551-1557
24. Taboureau O., Olsen O.H., Nielsen J.D., Raventos D., Mygind P.H., and Kristensen H.H. Design of novispirin antimicrobial peptides by quantitative structure-activity relationship. Chem Biol Drug Des 68 (2006) 48-57
25. Jenssen H., Lejon T., Hilpert K., Fjell C.D., Cherkasov A., and Hancock R.E. Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa. Chem Biol Drug Des 70 (2007) 134-142
26. Pasupuleti M., Walse B., Svensson B., Malmsten M., and Schmidtchen A. Rational design of antimicrobial C3a-analogs with enhanced effects against Staphylococci using an integrated structure and function-based approach. Biochemistry 47 (2008) 9057-9070
27. Nordahl E.A., Rydengard V., Nyberg P., Nitsche D.P., Morgelin M., Malmsten M., et al. Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci U S A 101 (2004) 16879-16884
28. Pasupuleti M., Walse B., Andersson Nordahl E., Mörgelin M., Malmsten M., and Schmidtchen A. Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. J Biol Chem 282 (2007) 2520-2528
29. Andersson Nordahl E., Rydengård V., Mörgelin M., and Schmidtchen A. Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem 41 (2005) 34832-34839
30. Malmsten M., Davoudi M., Walse B., Rydengård V., Pasupuleti M., Mörgelin M., et al. Antimicrobial peptides derived from growth factors. Growth Factors 25 (2007) 60-70
31. Malmsten M., Davoudi M., and Schmidtchen A. Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. Matrix Biol 25 (2006) 294-300
32. Strömstedt A.A., Pasupuleti M., Schmidtchen A., and Malmsten M. Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrobial Agents Chemother 53 (2009) 593-602
33. Sigurdadottir T., Andersson P., Davoudi M., Malmsten M., Schmidtchen A., and Bodelsson M. In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. Antimicrobial Agents Chemother 50 (2006) 2983-2989
34. Gregg S.J., and Sing K.S.W. Adsorption, surface area and porosity (1982), Academic Press, London p. 303
35. Galarneau A., Nader M., Guenneau F., di Renzo F., and Gedeon A. Understanding the stability in water of mesoporous SBA-15. J Phys Chem C 111 (2007) 8268-8277
36. Brinker C.J., and Scherer G.W. Sol-gel science: the physics and chemistry of sol-gel processing (1990), Academic Press, San Diego p. 617-75
37. Al-Oweini R., and El-Rossy H. Synthesis and characterization by FTIR spectroscopy of silica aerogels prepared using several Si(OR)4 and R″Si(OR′)3 precursors. J Mol Struct 919 (2009) 140-145
38. Slowing I., Trewyn B.G., and Lin V.S.Y. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc 128 (2006) 14792-14793
39. Chung T.H., Wu S.H., Yao M., Lu C.W., Lin Y.S., Hung Y., et al. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 28 (2007) 2959-2966
40. Wagner J.R., and Cañon M.C. Influence of denaturalization, hydrophobility and sulfydryl content on solubility and water absorbing capability of soy proteins insolates. J Food Sci 55 (2006) 765-770
41. Menaa B., Herrero M., Rives V., Lavrenko M., and Eggers D.K. Favourable influence of hydrophobic surface on proteins structure in porous organically-modified silica glasses. Biomaterials 29 (2008) 2710-2718
42. Crank J. The mathematics of diffusion. 2nd ed. (1975), Oxford University Press, Oxford p. 266-86
43. Kortesuo P., Ahola M., Karlsson S., Kangasniemi I., Yli-Urpo A., and Kiesvaara J. Silica xerogel as an implantable carrier for controlled drug delivery - evaluation of drug distribution and tissue effects after implantation. Biomaterials 21 (2000) 193-198
44. Patel P., Ide M., Coward P., and Di Silvio L. The effect of a commercially available chlorhexidine mouthwash product on human osteoblast cells. Eur J Prosthodont Restor Dent 14 (2006) 67-72